These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25557851)

  • 1. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
    Schmidt PJ; Racie T; Westerman M; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2015 Apr; 90(4):310-3. PubMed ID: 25557851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
    Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD
    Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
    Schmidt PJ; Liu K; Visner G; Fitzgerald K; Fishman S; Racie T; Hettinger JL; Butler JS; Fleming MD
    Am J Hematol; 2018 Jun; 93(6):745-750. PubMed ID: 29498084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
    Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G
    Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
    Schmidt PJ; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2021 Feb; 96(2):251-257. PubMed ID: 33180328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.
    Casu C; Aghajan M; Oikonomidou PR; Guo S; Monia BP; Rivella S
    Haematologica; 2016 Jan; 101(1):e8-e11. PubMed ID: 26405152
    [No Abstract]   [Full Text] [Related]  

  • 7. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.
    Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C
    Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
    Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
    Exp Toxicol Pathol; 2014 Sep; 66(7):333-43. PubMed ID: 24907196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exogenous iron increases hemoglobin in beta-thalassemic mice.
    Ginzburg YZ; Rybicki AC; Suzuka SM; Hall CB; Breuer W; Cabantchik ZI; Bouhassira EE; Fabry ME; Nagel RL
    Exp Hematol; 2009 Feb; 37(2):172-83. PubMed ID: 19059700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
    Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
    Olivieri NF; Brittenham GM; Matsui D; Berkovitch M; Blendis LM; Cameron RG; McClelland RA; Liu PP; Templeton DM; Koren G
    N Engl J Med; 1995 Apr; 332(14):918-22. PubMed ID: 7877649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
    Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
    Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.
    Casu C; Pettinato M; Liu A; Aghajan M; Lo Presti V; Lidonnici MR; Munoz KA; O'Hara E; Olivari V; Di Modica SM; Booten S; Guo S; Neil G; Miari R; Shapir N; Zafir-Lavie I; Domev H; Ferrari G; Sitara D; Nai A; Rivella S
    Blood; 2020 Oct; 136(17):1968-1979. PubMed ID: 32556142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.
    Hagag AA; Elfaragy MS; Elrifaey SM; Abd El-Lateef AE
    Infect Disord Drug Targets; 2015; 15(3):189-95. PubMed ID: 26239735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
    Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
    Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
    Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.
    Guo S; Casu C; Gardenghi S; Booten S; Aghajan M; Peralta R; Watt A; Freier S; Monia BP; Rivella S
    J Clin Invest; 2013 Apr; 123(4):1531-41. PubMed ID: 23524968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.